Expression of MMP-2 and TIMP‑3 with incidence and prognosis of giant-cell tumor of the bone

Liu,Zhendong; Ren,Yuxin; Zhu,Fuqiang

doi:10.3892/ol.2018.8696

Expression of MMP-2 and TIMP‑3 with incidence and prognosis of giant-cell tumor of the bone

Authors:
- Zhendong Liu
- Yuxin Ren
- Fuqiang Zhu
View Affiliations

Affiliations: Department of Orthopedics, Dezhou People's Hospital, Dezhou, Shandong 253014, P.R. China, Department of Spine Surgery, Dezhou People's Hospital, Dezhou, Shandong 253014, P.R. China
Published online on: May 10, 2018 https://doi.org/10.3892/ol.2018.8696
Pages: 721-726
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) in giant-cell tumor of bone (GCT), and the correlation of their expression with the clinicopathologic features and prognosis were investigated. A total of 70 GCT patients treated in our hospital from September, 2013 to September, 2015, were selected, and the tumor and para-carcinoma tissues were obtained by surgery. The expression levels of MMP-2 and TIMP-3 in GCT and para-carcinoma tissues were detected via semi-quantitative polymerase chain reaction (PCR) and western blot analysis, as well as immunohistochemical staining. Moreover, the clinicopathological data of the GCT patients were collected to study the correlation of MMP-2 and TIMP-3 with clinicopathological features and prognosis of GCT. The results of semi-quantitative PCR and western blot analysis revealed that the expression level of MMP-2 in tissues of the 70 GCT patients was significantly higher than that in para-carcinoma tissues, and the difference was statistically significant (P<0.01), while the expression level of TIMP-3 was obviously lower than that in para-carcinoma tissues (P<0.01). The results of immunohistochemical staining revealed that the positive expression rate of MMP-2 was 57.6% in GCT tissues and 18.9% in para-carcinoma tissues, while that of TIMP-3 was 63.2% in GCT tissues and 13.8% in para-carcinoma tissues, and the differences were statistically significant (P<0.01). The expression levels of MMP-2 and TIMP-3 were correlated with the diameter of tumor, clinical staging, lymph node metastasis and relapse of GCT (P<0.01), but were not correlated with the age and sex of GCT patients (P>0.05). There was a negative correlation between MMP-2 and TIMP-3 expression levels (r=-0.258, P<0.05). The expression levels of MMP-2 and TIMP-3 are closely related to the clinicopathological features and prognosis of patients, which can be used as one of the clinical examination indexes of GCT and also provide new insights for the clinical treatment of GCT.

View Figures

View References

1	Nicoli TK, Saat R, Kontio R, Piippo A, Tarkkanen M, Tarkkanen J and Jero J: Multidisciplinary approach to management of temporal bone giant cell tumor. J Neurol Surg Rep. 77:144–149. 2016. View Article : Google Scholar
2	Hu P, Zhao L, Zhang H, Yu X, Wang Z, Ye Z, Wu S, Guo S, Zhang G, Wang J, et al: Recurrence rates and risk factors for primary giant cell tumors around the knee: A multicentre retrospective study in China. Sci Rep. 6:363322016. View Article : Google Scholar : PubMed/NCBI
3	Gong HS, Liu GJ, Huang QS, Chen FH and Zhao HB: Surgical management of sacrococcygeal region giant tumors by use of balloon occlusion abdominal aorta. Turk Neurosurg. 26:904–911. 2016.PubMed/NCBI
4	Dabak N, Göçer H and Çıraklı A: Advantages of pressurized-spray cryosurgery in giant cell tumors of the bone. Balkan Med J. 33:496–503. 2016. View Article : Google Scholar : PubMed/NCBI
5	Rekhi B, Verma V, Gulia A, Jambhekar NA, Desai S, Juvekar SL, Bajpai J and Puri A: Clinicopathological features of a series of 27 cases of post-denosumab treated giant cell tumors of bones: A single institutional experience at a tertiary cancer referral centre, India. Pathol Oncol Res. 23:157–164. 2017. View Article : Google Scholar : PubMed/NCBI
6	Parra-Herran C1, Schoolmeester JK, Yuan L, Dal Cin P, Fletcher CD, Quade BJ and Nucci MR: Myxoid leiomyosarcoma of the uterus: A clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms. Am J Surg Pathol. 40:285–301. 2016. View Article : Google Scholar : PubMed/NCBI
7	Yang L, Zheng Z, Zhou Q, Bai X, Fan L, Yang C, Su L and Hu D: miR-155 promotes cutaneous wound healing through enhanced keratinocytes migration by MMP-2. J Mol Histol. 48:147–155. 2017. View Article : Google Scholar : PubMed/NCBI
8	Adhikari N, Mukherjee A, Saha A and Jha T: Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview. Eur J Med Chem. 129:72–109. 2017. View Article : Google Scholar : PubMed/NCBI
9	Rother S, Samsonov SA, Moeller S, Schnabelrauch M, Rademann J, Blaszkiewicz J, Köhling S, Waltenberger J, Pisabarro MT, Scharnweber D and Hintze V: Sulfate hyaluronan alters endothelial cell activation in vitro by controlling the biological activity of the angiogenic factors vascular endothelial growth factor-A and tissue inhibitor of metalloproteinase-3. ACS Appl Mater Interfaces. 9:9539–9550. 2017. View Article : Google Scholar : PubMed/NCBI
10	Shooshtarizadeh T, Rahimi M and Movahedinia S: P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions. Pathol Res Pract. 212:876–879. 2016. View Article : Google Scholar : PubMed/NCBI
11	Qi DW, Wang P, Ye ZM, Yu XC, Hu YC, Zhang GC, Yan XB, Zheng K, Zhao LM and Zhang HL: Clinical and radiographic results of reconstruction with fibular autograft for distal radius Giant Cell Tumor. Orthop Surg. 8:196–204. 2016. View Article : Google Scholar : PubMed/NCBI
12	Hu Y, Zhao L, Zhang H, Yu X, Wang Z, Ye Z, Wu S, Guo S, Zhang G, Wang J and Ning X: Sex differences in the recurrence rate and risk factors for primary giant cell tumors around the knee in China. Sci Rep. 6:281732016. View Article : Google Scholar : PubMed/NCBI
13	Pujani M, Bahadur S, Jairajpuri ZS, Jetley S and Jameel J: Giant cell tumor bone in an elderly male - an unusual case misdiagnosed on MRI as a malignant sarcoma. Indian J Surg Oncol. 6:285–287. 2015. View Article : Google Scholar : PubMed/NCBI
14	Almalki SG, Valle Llamas Y and Agrawal DK: MMP-2 and MMP-14 silencing inhibits VEGFR2 cleavage and induces the differentiation of porcine adipose-derived mesenchymal stem cells to endothelial cells. Stem Cells Transl Med. 6:1385–1398. 2017. View Article : Google Scholar : PubMed/NCBI
15	Yadav PK, Yadav BS, Panigrahi PN, Tripathi V, Chaturvedi N and Kataria M: Molecular characterization and in-silico analysis of the tissue inhibitor of metalloproteinases-3 (TIMP-3) gene of canine mammary tumor. Comb Chem High Throughput Screen. 60:686–691. 2017.
16	Su CW, Su BF, Chiang WL, Yang SF, Chen MK and Lin CW: Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression. Int J Med Sci. 14:37–44. 2017. View Article : Google Scholar : PubMed/NCBI
17	Sharma K, Tyagi R, Singh R, Sharma SK and Anand A: Serum levels of TIMP-3, LIPC, IER3 and SLC16A8 in CFH negative AMD cases. J Cell Biochem. 118:2087–2095. 2017. View Article : Google Scholar : PubMed/NCBI
18	Lin HF, Hsi E, Huang LC, Liao YC, Juo SH and Lin RT: Methylation in the matrix metalloproteinase-2 gene is associated with cerebral ischemic stroke. J Investig Med. 65:794–799. 2017. View Article : Google Scholar : PubMed/NCBI
19	Pillai SS, Yukawa H, Onoshima D, Biju V and Baba Y: Förster resonance energy transfer mediated photoluminescence quenching in stoichiometrically assembled CdSe/ZnS quantum dot-peptide labeled black hole quencher conjugates for matrix metalloproteinase-2 sensing. Anal Sci. 33:137–142. 2017. View Article : Google Scholar : PubMed/NCBI
20	Liu D, Zhang R, Wu J, Pu Y, Yin X, Cheng Y, Wu J, Feng C, Luo Y and Zhang J: Interleukin-17A promotes esophageal adenocarcinoma cell invasiveness through ROS-dependent, NF-κB-mediated MMP-2/9 activation. Oncol Rep. 37:1779–1785. 2017. View Article : Google Scholar : PubMed/NCBI